Abstract
Signatera™ is a personalized commercial assay that detects circulating tumor DNA (ctDNA) and has shown molecular residual disease (MRD) in colorectal and urothelial cancer. However, it is unknown whether Signatera™ could detect ctDNA in anaplastic (ATC) and medullary thyroid cancer (MTC) due to their low mutation burden.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
